R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond

Antiviral Research

Volumn 78, Issue 3, 2008, Pages 278-281

  Thys, Bert ^a   De Palma, Armando M ^b   Neyts, Johan ^b   Andries, Koen ^c   Vrijsen, Raf ^a   Rombaut, Bart ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Anti poliovirus compound; Picornavirus; Polio eradication; Poliovirus; Pyridazinamine analogue

Indexed keywords

ANTIVIRUS AGENT; PYRIDAZINAMINE DERIVATIVE; R 75761; R 78206; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; POLIOMYELITIS VIRUS 2; POLIOMYELITIS VIRUS 3; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOPATHOGENIC EFFECT, VIRAL; HELA CELLS; HUMANS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; PYRIDAZINES; VIRUS REPLICATION;

HUMAN POLIOVIRUS 1; PICORNAVIRIDAE; POLIOVIRUS;

EID: 41049101159     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.01.002     Document Type: Article

References (16)

1. Agol V.I. Vaccine-derived polioviruses. Biologicals 34 (2006) 103-108
2. Andries K. Discovery of pirodavir, a broad-spectrum inhibitor of rhinoviruses. In: Adams J., and Merluzzi V.J. (Eds). The Search for Antiviral Drugs (1993), Birkhauser, Boston, MA 179-209
3. Andries K., Dewindt B., Snoeks J., and Willebrords R. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization. Arch. Virol. 106 (1989) 51-61
4. Andries K., Dewindt B., Snoeks J., Willebrords R., van Eemeren K., Stokbroekx R., and Janssen P.A. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob. Agents Chemother. 36 (1992) 100-107
5. Barnard D.L. Current status of anti-picornavirus therapies. Curr. Pharm. Des. 12 (2006) 1379-1390
6. Barnard D.L., Hubbard V.D., Smee D.F., Sidwell R.W., Watson K.G., Tucker S.P., and Reece P.A. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob. Agents Chemother. 48 (2004) 1766-1772
7. Committee on Development of a Polio Antiviral and its Potential Role in Global Poliomyelitis Eradication, N.R.C. (2006). Exploring the Role of Antiviral Drugs in the Eradication of Polio: Workshop Report. The National Academies Press, Washington, D.C.
8. De Palma, A.M., Pürstinger, G., Patick, A., Andries, K., Rombaut, B., De Clercq, E., Neyts, J., 2008. Comparative activity of a series of anti-enteroviral compounds against poliovirus replication in vitro. Emerg. Infect. Dis., in press.
9. Halsey N.A., Pinto J., Espinosa-Rosales F., Faure-Fontenla M.A., da Silva E., Khan A.J., Webster A.D., Minor P., Dunn G., Asturias E., Hussain H., Pallansch M.A., Kew O.M., Winkelstein J., and Sutter R. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull. World Health Organ. 82 (2004) 3-8
10. Jiang P., Faase J.A., Toyoda H., Paul A., Wimmer E., and Gorbalenya A.E. Evidence for emergence of diverse polioviruses from C-cluster coxsackie A viruses and implications for global poliovirus eradication. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 9457-9462
11. Kew O., Morris-Glasgow V., Landaverde M., Burns C., Shaw J., Garib Z., André J., Blackman E., Freeman C.J., Jorba J., Sutter R., Tambini G., Venczel L., Pedreira C., Laender F., Shimizu H., Yoneyama T., Miyamura T., van Der Avoort H., Oberste M.S., Kilpatrick D., Cochi S., Pallansch M., and de Quadros C. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 296 (2002) 356-359
12. McKinlay M.A., Pevear D.C., and Rossmann M.G. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu. Rev. Microbiol. 46 (1992) 635-654
13. Rombaut B., Andries K., and Boeyé A. Stabilisation of poliovirus with pirodavir. Dev. Biol. Stand. 87 (1996) 173-180
14. Watson K.G., Brown R.N., Cameron R., Chalmers D.K., Hamilton S., Jin B., Krippner G.Y., Luttick A., McConnell D.B., Reece P.A., Ryan J., Stanislawski P.C., Tucker S.P., Wu W.Y., Barnard D.L., and Sidwell R.W. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J. Med. Chem. 46 (2003) 3181-3184
15. World Health Assembly, 1988. Global eradication of poliomyelitis by the year 2000: resolution of the 41st World Health Assembly. Resolution WHA 41.28. World Health Organization, Geneva, Switzerland.
16. World Health Organization, 2002. Progress towards the global eradication of poliomyelitis, 2001. Wkly. Epidemiol. Rec. 77, 98-107.